Your choice for preclinical high throughput testing of human iPSC-derived cardiomyocyte contractile behavior!
contractility service anchor
Our contractility service based on the FLEXcyte 96 platform is an end-to-end cardiac safety, toxicity and efficacy testing service with your drug candidate(s). We plan, prepare and conduct your contractility study!
Predictive Cell Model on a Higher Throughput System
HiPSC-derived cardiomyoctes are currently used in a variety of assays to improve cardiotoxicity guidelines in a CiPA (Comprehensive in vitro Proarrhythmia Assay) conform manner. We have validated a broad range of commercially available and CiPA accepted human iPSC-derived cardiomyocytes as most predictive cell model for the FLEXcyte 96 Service – a cardiac contractility assay on a higher throughput 96 well plate for cardiac safety, cardiotox as well as drug discovery purposes. We also welcome your in-house hiPSC cardiomyocytes to test and characterize.
Mature Cardiac Phenotype for Reliable Adult-Like Drug Responses
example data anchor
Drug induced adult-like responses of human iPSC-derived cardiomyocytes usually fail due to the immature phenotype of the cells. The flexible membranes of the FLEXcyte 96 plates form a natural biohybrid layer with the cells and provide a unique and necessary auxotonic environment in vitro to promote cell maturation. Mature cardiomyocyte responses on FLEXcyte 96 plates with commercially available human iPSC-derived cardiomyocytes can be detected upon treatment with positive inotropic compounds like isoproterenol and S-Bay K8644.
Acute & Chronic Testing of Your Drug Candidates
Dependend on the biological mechanism of your drug candidates, acute or chronic assessment of cardiac contractility may be necessary. The FLEXcyte 96 service provides acute and chronic measurements, conducted from minutes up to one week after compound addition. The settings are adjustable for drug discovery as well as safety pharmacology studies and preclinical toxicology testing. Each study is tailored to your needs.
Tailored Study Report Covering All Parameters
The FLEXcyte technology delivers a comprehensive set of parameters measured on the cardiomyocyte contractility behavior. Parameters measured are Beat Rate, Beat Duration, Upstroke and Downstroke Velocity, Upstroke and Downstroke AUC, Arrhythmic Events as well as proper Contraction Force (mN/mm2). Our experts will deliver a full study report containing the essential study parameters and results of your drug candidates to evaluate drug discovery / preclinical cardiac risk potential.
Dowload our FLEXcyte 96 service flyer here: FLEXcyte 96 - Safety and Toxicity Service Flyer
Dowload our FLEXcyte 96 contraction force flyer here: FLEXcyte 96 - Contractile Force Flyer
cell line characterization anchor